Wells Fargo’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.7K | Hold |
19,800
| – | – | ﹤0.01% | 5776 |
|
|
2025
Q4 | $26.9K | Hold |
19,800
| – | – | ﹤0.01% | 5711 |
|
|
2025
Q3 | $31.7K | Buy |
19,800
+14,292
| +259% | +$23.3K | ﹤0.01% | 5682 |
|
|
2025
Q2 | $7.71K | Sell |
5,508
-14,818
| -73% | -$22.2K | ﹤0.01% | 6012 |
|
|
2025
Q1 | $32.7K | Buy |
20,326
+332
| +2% | +$421 | ﹤0.01% | 5530 |
|
|
2024
Q4 | $25.2K | Buy |
19,994
+5,435
| +37% | +$8.43K | ﹤0.01% | 5700 |
|
|
2024
Q3 | $27.4K | Sell |
14,559
-365
| -2% | -$1.44K | ﹤0.01% | 5547 |
|
|
2024
Q2 | $110K | Buy |
14,924
+1,257
| +9% | +$10.3K | ﹤0.01% | 4877 |
|
|
2024
Q1 | $107K | Buy |
13,667
+1,224
| +10% | +$7.87K | ﹤0.01% | 4851 |
|
|
2023
Q4 | $63.2K | Buy |
12,443
+1,736
| +16% | +$8.94K | ﹤0.01% | 5177 |
|
|
2023
Q3 | $63.4K | Sell |
10,707
-5,394
| -34% | -$35.9K | ﹤0.01% | 5052 |
|
|
2023
Q2 | $119K | Buy |
16,101
+10,625
| +194% | +$90.4K | ﹤0.01% | 4925 |
|
|
2023
Q1 | $51.7K | Buy |
5,476
+4
| +0.1% | +$42 | ﹤0.01% | 5144 |
|
|
2022
Q4 | $58.3K | Buy |
5,472
+405
| +8% | +$4.11K | ﹤0.01% | 4793 |
|
|
2022
Q3 | $37K | Buy |
5,067
+8
| +0.2% | +$50 | ﹤0.01% | 5086 |
|
|
2022
Q2 | $25K | Buy |
5,059
+23
| +0.5% | +$131 | ﹤0.01% | 5337 |
|
|
2022
Q1 | $26K | Buy |
5,036
+1
| +0% | +$5 | ﹤0.01% | 5920 |
|
|
2021
Q4 | $30K | Sell |
5,035
-475
| -9% | -$3.56K | ﹤0.01% | 6184 |
|
|
2021
Q3 | $49K | Buy |
5,510
+3,961
| +256% | +$27.5K | ﹤0.01% | 5635 |
|
|
2021
Q2 | $12K | Buy |
1,549
+175
| +13% | +$1.37K | ﹤0.01% | 6074 |
|
|
2021
Q1 | $11K | Sell |
1,374
-16,006
| -92% | -$136K | ﹤0.01% | 6305 |
|
|
2020
Q4 | $136K | Buy |
17,380
+16,811
| +2,954% | +$183K | ﹤0.01% | 5238 |
|
|
2020
Q3 | $6K | Buy |
569
+48
| +9% | +$529 | ﹤0.01% | 5973 |
|
|
2020
Q2 | $5K | Hold |
521
| – | – | ﹤0.01% | 5964 |
|
|
2020
Q1 | $3K | Buy |
521
+34
| +7% | +$242 | ﹤0.01% | 5921 |
|
|
2019
Q4 | $3K | Buy |
+487
| New | +$3.36K | ﹤0.01% | 6103 |
|
|
2015
Q3 | – | Sell |
-122
| Closed | -$10K | – | 6186 |
|
|
2015
Q2 | $10K | Buy |
122
+63
| +107% | +$5.38K | ﹤0.01% | 5801 |
|
|
2015
Q1 | $4K | Buy |
59
+26
| +79% | +$3.09K | ﹤0.01% | 5857 |
|
|
2014
Q4 | $6K | Hold |
33
| – | – | ﹤0.01% | 5800 |
|
|
2014
Q3 | $7K | Sell |
33
-14
| -30% | -$2.78K | ﹤0.01% | 5716 |
|
|
2014
Q2 | $10K | Buy |
+47
| New | +$15.7K | ﹤0.01% | 5632 |
|
Other funds holding ATNM
VCM
GS
VFT
Wells Fargo's ATNM Position: Q1 2026 in Review
Wells Fargo held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 19,800 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5776.
Wells Fargo first reported a position in ATNM in Q2 2014 and has held it in 31 quarters since. The position peaked at $136K in Q4 2020. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.
- Wells Fargo held 19,800 shares of Actinium Pharmaceuticals worth $19.7K as of Q1 2026.
- Wells Fargo left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
- Actinium Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5776 holding.
- Wells Fargo first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 31 quarters since.
- Wells Fargo's Actinium Pharmaceuticals position peaked at $136K in Q4 2020.
- 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.